1/29
06:16 am
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
10:32 am
artv
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
Low
Report
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
1/21
08:00 am
artv
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
Medium
Report
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
1/15
08:29 pm
artv
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored [Seeking Alpha]
Medium
Report
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored [Seeking Alpha]
1/8
03:30 am
artv
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Low
Report
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
1/8
03:30 am
artv
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Low
Report
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
12/19
06:30 pm
artv
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO's Latest Insider Share Sale [Yahoo! Finance]
Medium
Report
Artiva Biotherapeutics (ARTV): Evaluating Valuation After CEO's Latest Insider Share Sale [Yahoo! Finance]
12/14
06:16 am
artv
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
High
Report
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
11/22
07:56 am
artv
Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
11/12
02:21 pm
artv
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
11/12
10:31 am
artv
Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]
High
Report
Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]
11/12
08:21 am
artv
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]
Medium
Report
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]
11/12
07:20 am
artv
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
High
Report
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
11/12
07:00 am
artv
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
High
Report
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights